Piper Sandler analyst Clarke Jeffries reiterates Olo (NYSE:OLO) with a Neutral and maintains $9 price target.
Vaccinex Shares Spike Higher; Co. Tweeted ‘Vaccinex is currently conducting 2 ongoing clinical trials: our Phase 1b/2 SIGNAL-AD trial of pepinemab for #AlzheimersDisease and our Phase 1b/2 Keynote B84 trial of pepinemab’
https://twitter.com/Vaccinex/status/1531700798446612484